Ourresultsprovide a unique paradigmforiPSC-factor-basedreprogrammingby demonstrating that it can be readily modified to serve as a generalplatformfor transdifferentiation.
But then you would downsize the scale of the clinical trial ten-fold, if you directed the drug mainly at patients most likely to respond to it based on the iPSC patient studies.